Recursion Pharmaceuticals, Inc. (RXRX) on Decifer

Why it ranks here

• Sales are growing about 33% a year, faster than 82 in 100 companies we measure.
• It costs about 42 times its yearly sales; the middle of its industry is 9. Cheaper than 5 in 100 companies we measure, against their own industries.

The current read

The evidence on RXRX lines up on the supportive side: the intelligence feed flags this name as connected to what is moving markets now. The independent signals we track are telling the same story.

Read the full RXRX research brief · See all quality rankings

Intelligence data powered by Decifer. Not financial advice. For informational purposes only.